Cucurbitacins which are structurally unlike triterpenes found in the members of Cucurbitaceae and several other plant families possess immense pharmacological activity. This diverse group of compounds may substantiate to be important lead molecules for the treatment of cancer. Research focused on these unattended medicinal compounds can prove the significance and explore the hidden potential to cure various diseases. These compounds show their proposed mode of action, probable molecular targets and have future aspects of their use as a medicinal agent. This review is aimed to provide the chemical nature and medicinal property of cucurbitacins.
INTRODUCTION
Medicinal plants are the nature's gift to human being to cure disease and make disease free life. Herbal medicine is still the backbone of about 75-80% of the total population ). Plant's secondary metabolites are important sources for scientific and clinical study as well as for new drug development. Many plant synthesized herbal medicines in different formulations used for treatment of various diseases from an ancient time. Traditional or indigenous drugs have special importance. Phytochemicals as secondary metabolites and they can be used in the pharmaceutical industries for producing a potent drug (Nag M et al., 2018) . Terpenes are volatile organic compounds which are the major odoriferous constituents of essential oil and e contain two or more 5-carbon isoprene units. Many terpenes contain additional functioning groups, such as carboxyl (COOH), carbonyl (CO), alkoxy (OR) and hydroxyl (OH). It is tested over a long time, and are relatively safe, easily available and affordable (Kupchan, Meshulam, & Sneden, 1978) . Many ethnobotanical survey reported that, the local population in different parts of the world including the USA, China, India, Mexico, Morocco, Saudi Arabia, Taiwan, and Trinidad and Tobago depend on medicinal plant and suggested that several medicinal plants have been used as dietary adjuncts for the cure of numerous chronic and severe disease (H Stuppner & Moller, 1993) . In India and China, the use of herbal medicines has been commonly used from a long time, as a less expensive way to treat various health problems. The herbal drugs are less toxic with limited side effects compared with synthetic drugs (DINAN et al., 1997) . Due to such reasons, traditional and complementary medicines have seen an increase in their popularity for the treatment of different diseases. The WHO has also recommended the initiation of studies to identify and characterize new herbal preparations from traditionally known plants and the development of new effective therapeutic agents, especially in the areas where the lack of safe modern drugs to treat chronic diseases. Cancer is a chronic disease and serious health threats for about seven million people in a year and a big challenge medical science (Makar, Saha, & Singh, 2018 
CHEMISTRY OF CUCURBITACINS

Induction of Cell Cycle Arrest:
In human cells, cell cycle transition is controlled by holoenzymes consisting of both regulatory (cyclin) and catalytic (cyclin-dependent kinase (CDK)) subunits. CDK inhibitors CDK1, p21=Waf1 and p27KIP1 act as key regulators of the cell cycle by binding to CDK complexes and decreasing kinase activity. Cucurbitacins induce cell cycle arrest by modulating multiple signaling pathways (Bowman et al., 1999) . Cucurbitacin B induces G2/M cell cycle arrest in various cancers, including osteosarcoma (OS) cell, non-small cell lung cancer, breast cancer, cutaneous squamous cell carcinoma, glioblastoma multiform, laryngeal squamous cell carcinoma and pancreatic cell . In hepatocellular carcinoma cells, the Cucurbitacin Binduced cell cycle arrest in S phase is related to a significant decline in cyclin 1 and C C2 levels, and no change in cyclin B1 level, which is different from the other cell lines, indicating that cucurbitacin B is probably cell specific in mediating inhibition of cell growth. In breast cancer cells, Cucurbitacin B arrests cell cycle by inhibiting telomerase via the downregulation of human telomerase reverse transcriptase and c-Myc, as well as up-regulation of p21, Waf1 and p27Kip1 expression via the defective gene BRCA1. In addition, Cucurbitacin B downregulates protein expression of cyclin B1 and CDC25C without reducing CDK1 expression in colon adenocarcinoma SW480 cells nor increasing p53 and p21 expression in neuroblastoma .In non-small lung cancer cells, Cucurbitacin B exerts its effect on cell cycle arrest through the down-regulation of CDK1, cyclin D1, and PCNA proteins. Cucurbitacin I decreases the expression of cell cycle proteins including cyclin B1, cyclin A, CDK1, and CDC25C in colon cancer cells (SW480). These results indicate that different cell types treated with cucurbitacins may not use the same mechanism to trigger cell cycle arrest (Bowman, Garcia, Turkson, & Jove, 2000) . Furthermore, the microtubule cytoskeletons are relevant to cell motility and cytokinesis in various cancers. he formation of cofilin-actin rods induced by cucurbitacin B is regulated by chronophin in dependent, but cofilin phosphatase Slingshot homolog 1-dependent hyper activation of cofilin in melanoma, leading to cancer cell growth arrest and inhibition of migration also, cucurbitacin B significantly changes cytoskeletal network in breast cancer and glioblastoma multiforme cells, which induces incorrect polymerization of microtubule network and fast morphologic changes (Dong et al., 2010) . In the cells treated with cucurbitacin B, the Gactin pool is rapidly depleted and actin aggregates are quickly formed through the activation of a ROS dependent mechanism that regulates various cytoskeleton-regulatory proteins, ultimately leading to anticancer effects. Similar to cucurbitacin B, cucurbitacin IIa is a class of anticancer agent that inhibits cell survival in cancer by embroiling the actin cytoskeleton. Cell cycle arrest in G2/M phase was induced by cucurbitacin D and IIa in breast cancer. In Nf2-deficient meningioma and schwannoma cells, cucurbitacin D decreases cyclin A, B, and E and inhibits expression of phospho-PRAS40 and phosphoAkt (Duncan, Duncan, Alley, & Sausville, 1996) . Furthermore, cucurbitacin D increases p21Waf1 as well as p27Kip1 proteins and decreases cyclin A and B in endometrial and ovarian cancer cells. In human bladder cancer T24, pancreatic, ovarian, and breast cancer cells, cell cycle arrest in G2/M phase induced by cucurbitacin E is related to a significant increase in the levels of p27, p21, and p53 along with inactivation of STAT3, CDK1, and cyclin B. Additionally, cucurbitacin E blocks cyclin B1/CDC2 complex formation and induces the expression of GADD45 in colorectal and human brain malignant gliomas cells, indicating that the delay of mitosis by cucurbitacin E is regulated by the overexpression of the GADD45 gene family (Duangmano et al., 2010) .
Inhibition of Cancer Invasion and Migration:
Cancer metastasis is a complicated process including cell migration, adhesion, and proteolysis of the basement membrane (BM) and extracellular matrix (ECM). In particular, the matrix metalloproteinase (MMP) family accounts for degradation of the Vol. 7, Issue 2 | pharmatutorjournal.com Growth inhibition and cytotoxic effect of cucurbitacin B on breast cancer cell lines SKBR-3 and MCF-7 were attributed to G2/M phase arrest and apoptosis. Cucurbitacin B treatment inhibited Cyclin D1, c-Myc, and β-catenin expression levels, translocation to the nucleus of β-catenin and galectin-3. Western blot analysis showed increased PARP cleavage suggesting induced caspase activity and decreased mutagenic Wnt-associated signaling molecules galectin-3, β-catenin, c-Myc, and cyclin D1 with changes in phosphorylated GSK-3β levels (Esterbauer, 1993) negative side effects, such as the presence of an acetoxyl group at C25, the double bond at C23, or the presence of a carbonyl or hydroxyl at C3, which can modify both the cytotoxicity and the pharmacological activity of cucurbitacins. The most interesting structures for obtaining new cytotoxic compounds are probably cucurbitacin B and E whereas the deacetyl-derivatives (e.g. cucurbitacin R) show the highest potential as the basis for a series of anti-inflammatory cucurbitacins. The different studies conducted on cucurbitacins and the similarity of the results shows that these compounds are a selective kind of JAK/STAT pathway inhibitor and that they may be highly interesting for treating cancers in which this pathway is implicated, such as human lung adenocarcinoma, glioblastoma multiform, nasopharyngeal carcinoma, or chronic lymphocytic leukemia Many studies have postulated that the concomitant use of different cucurbitacins, especially I and B, could improve the effects of gemcitabine, methotrexate, docetaxel, or cisplatin, which could allow for a possible reduction in dosage in order to avoid the high number of undesirable effects of these drugs. For these reasons, pumpkin seed show promise as anticancer agents, especially in combination with other therapeutic agents when chemo-resistance and radio-resistance constitute a serious problem for the patient. Cucurbitacins thus have a great potential for use as pharmacological agents in the prevention and treatment of cancer. In addition, they constitute a selective laboratory tool for studying compounds implicated in the JAK/STAT pathway and they will also be beneficial for database development and template design for future drug development. The purpose of this review is to gather the information about an anticancer potential related to these highly diverse group of Cucurbitacin which may be useful in future research.
